98% Min TSU 68 Orantinib VEGFR Inhibitor Cas 252916-29-3
98% Min TSU 68 Orantinib VEGFR Inhibitor Cas 252916-29-3
+ AII PRODUCTS
- Prostaglandins - Custom Synthesis - PARP Inhibitors - PI3K Inhibitors - FAK Inhibitors - AKT Inhibitors - C-Kit Inhibitors - VEGFR Inhibitors - c-Met Inhibitors - CDK Inhibitors - CYP17 Inhibitors - DNA/RNA Inhibitors - mTOR Inhibitors - SRC Inhibitors - Others
Product
|
Size |
Price |
Stock |
Quantity |
|---|---|---|---|
|
Get Quotation Now Add to Cart Bulk Inquiry |
|||
AddThis Sharing Buttons
Share to FacebookFacebookShare to TwitterTwitterShare to PrintPrintShare to EmailEmailShare to PinterestPinterestShare to GmailGmailShare to LinkedInLinkedInShare to Email AppEmail AppShare to TumblrTumblrShare to MoreAddThis
Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.
Chemical Information
|
Product name:TSU-68 Orantinib |
Purity:98% min |
|
CAS NO:252916-29-3 |
Solubility:DMSO28 mg/mL (90.22 mM) |
|
Molecular Formula:C18H18N2O3 |
Package:Package according to customer requirements |
|
Molecular Weight:310.347 |
Storage:Store at -20℃ |
Quality control
Remarks
Orantinib, also known as TSU-68SU6668, is an orally bioavailable receptor tyrosine kinase inhibitor. Orantinib binds to and inhibits the autophosphorylation of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR), thereby inhibiting angiogenesis and cell proliferation. Orantinib also inhibits the phosphorylation of the stem cell factor receptor tyrosine kinase c-kit, often expressed in acute myelogenous leukemia cells. Check for active clinical trials or closed clinical trials using this agent.
Related Prodcuts:
LY2874455; ZM-306416; ZM323881; Tyrphostin A9; Brivanib; Foretinib; SU5402; Semaxanib; SAR131675; Lucitanib; Apatinib; SKLB610; Altiratinib; SGI-7079; AZD2932
References
[1].Laird AD, et al. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res, 2000, 60(15), 4152-4160.
[2].Smolich BD, et al. The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts. Blood, 2001, 97(
Get in Touch
Have questions about our products or want to discuss a custom order? Our team is ready to help you.